Compare LOOP & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LOOP | BOLD |
|---|---|---|
| Founded | 2010 | 2018 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.2M | 36.5M |
| IPO Year | 2010 | 2024 |
| Metric | LOOP | BOLD |
|---|---|---|
| Price | $1.42 | $1.44 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 43.3K | ★ 130.1K |
| Earning Date | 05-28-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 27.27 | ★ 32.47 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $10,889,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $174.82 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 7016.99 | N/A |
| 52 Week Low | $0.88 | $0.96 |
| 52 Week High | $2.29 | $1.68 |
| Indicator | LOOP | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 54.66 | 50.66 |
| Support Level | $1.41 | $1.40 |
| Resistance Level | $1.50 | $1.55 |
| Average True Range (ATR) | 0.09 | 0.07 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 70.18 | 36.59 |
Loop Industries Inc. is a technology and licensing company whose mission is to accelerate the world's shift toward sustainable plastic and away from dependence on fossil fuels. The company owns patented and proprietary technology that depolymerizes no and low value waste PET plastic and polyester fiber, including plastic bottles and packaging, carpet and polyester textile of any color, transparency or condition, and even ocean plastics that have been degraded by the sun and salt, to its base building blocks.
Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.